CAMH-2 is under clinical development by Precirix and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CAMH-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CAMH-2 overview

CAMH-2 is under development for the treatment of metastatic HER2 positive breast cancer, gastric cancer and gastroesophageal (GE) junction carcinomas. The drug candidate is an antigen-binding fragment derived from camelid heavy-chain-only antibodies targeting human epidermal growth factor receptor 2 (HER2) labeled with radioisotope iodine I131 using the residualizing radio-iodinating reagent N-succinimidyl 4-guanidinomethyl 3-iodobenzoate (SGMIB). Camelid derived probes are used to transport radioisotopes to selected target receptors on the cancer cell surface. The drug candidate is being developed based on sdAbs technology platform administered through intravenous route.

Precirix overview

Precirix, formerly Camel-IDS is a biotechnology company that develops radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer. The company’s lead product candidate CAM-H2 is used for the treatment of HER2-positive cancers. Its technology platform is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies coupled with radioisotope to kill cancer cells. Its pipeline products provide delivery of therapeutic radiation to cancer cells, while sparing healthy tissues. It works in collaborations with clinical research institutions and organizations. The company is a spin-off from Vrije Universiteit Brussel (VUB). Precirix is headquartered in Brussels, Bruxelles-Capitale, Belgium.

For a complete picture of CAMH-2’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.